W.G. Shaheen & Associates DBA Whitney & Co raised its position in CVS Health Corp (NYSE:CVS) by 0.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,007 shares of the pharmacy operator’s stock after acquiring an additional 280 shares during the quarter. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in CVS Health were worth $2,495,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Gemmer Asset Management LLC lifted its stake in shares of CVS Health by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after buying an additional 200 shares during the last quarter. TB Alternative Assets Ltd. acquired a new stake in shares of CVS Health during the 2nd quarter worth about $121,000. Captrust Financial Advisors acquired a new stake in shares of CVS Health during the 2nd quarter worth about $155,000. SRS Capital Advisors Inc. lifted its stake in shares of CVS Health by 48.2% during the 1st quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock worth $177,000 after buying an additional 734 shares during the last quarter. Finally, Grace & White Inc. NY acquired a new stake in shares of CVS Health during the 2nd quarter worth about $199,000. Hedge funds and other institutional investors own 82.24% of the company’s stock.

In other news, EVP Thomas M. Moriarty sold 90,267 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.61, for a total value of $7,186,155.87. Following the sale, the executive vice president now directly owns 70,102 shares in the company, valued at approximately $5,580,820.22. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jonathan C. Roberts sold 85,743 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the completion of the sale, the chief operating officer now owns 119,555 shares in the company, valued at $9,939,802.70. The disclosure for this sale can be found here. Over the last three months, insiders sold 714,125 shares of company stock worth $58,119,381. Insiders own 0.61% of the company’s stock.

CVS Health Corp (NYSE:CVS) opened at $71.69 on Tuesday. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. CVS Health Corp has a 1-year low of $66.45 and a 1-year high of $84.72. The company has a market cap of $76,095.96, a PE ratio of 13.16, a price-to-earnings-growth ratio of 1.29 and a beta of 0.89.

CVS Health (NYSE:CVS) last released its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same period last year, the firm earned $1.64 EPS. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. equities research analysts predict that CVS Health Corp will post 5.9 earnings per share for the current year.

A number of research firms have recently issued reports on CVS. Jefferies Group set a $76.00 target price on shares of CVS Health and gave the stock a “hold” rating in a research note on Monday. Deutsche Bank restated a “hold” rating on shares of CVS Health in a research note on Tuesday. Needham & Company LLC raised their target price on shares of CVS Health from $79.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday. Loop Capital set a $73.00 target price on shares of CVS Health and gave the stock a “hold” rating in a research note on Monday. Finally, Robert W. Baird set a $77.00 price target on shares of CVS Health and gave the stock a “hold” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $86.35.

WARNING: This piece of content was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://theolympiareport.com/2017/12/05/cvs-health-corp-cvs-holdings-increased-by-w-g-shaheen-associates-dba-whitney-co.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.